Net Cash Provided by (Used in) Financing Activities of Perspective Therapeutics, Inc. from 30 Sep 2010 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Perspective Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 30 Sep 2010 to 31 Mar 2025.
  • Perspective Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $9,973,000, a 94% decline year-over-year.
  • Perspective Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $289,385,000, a 36764% increase from 2023.
  • Perspective Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $785,000, a 2704% increase from 2022.
  • Perspective Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $28,000, a 100% decline from 2021.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

Perspective Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $9,973,000 -$156,355,000 -94% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q1 2024 $166,328,000 +$166,408,000 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q1 2023 $80,000 -$80,000 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q3 2022 $28,000 +$28,000 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2022 2023 Q1
Q1 2022 $0 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q3 2021 $0 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2023 Q1
Q3 2018 $7,494,000 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2020 Q1
Q3 2013 $3,280,888 -$20,626 -0.62% 01 Jul 2013 30 Sep 2013 10-Q 14 Nov 2013 2014 Q1
Q3 2012 $3,301,514 +$3,261,270 +8104% 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2014 Q1
Q3 2011 $40,244 +$52,163 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2012 2013 Q1
Q3 2010 $11,919 01 Jul 2010 30 Sep 2010 10-Q/A 13 Dec 2011 2012 Q1

Perspective Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $289,385,000 +$288,600,000 +36764% 01 Jan 2024 31 Dec 2024 10-K/A 28 Mar 2025 2024 FY
2023 $785,000 +$757,000 +2704% 01 Jan 2023 31 Dec 2023 10-K/A 28 Mar 2025 2024 FY
2022 $28,000 -$64,656,000 -100% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $64,684,000 +$63,690,000 +6407% 01 Jul 2020 30 Jun 2021 10-KT 01 May 2023 2023 Q1
2020 $994,000 -$6,380,000 -87% 01 Jul 2019 30 Jun 2020 10-KT 01 May 2023 2023 Q1
2019 $7,374,000 +$6,853,000 +1315% 01 Jul 2018 30 Jun 2019 10-K 27 Sep 2021 2021 FY
2018 $521,000 +$530,000 01 Jul 2017 30 Jun 2018 10-K 25 Sep 2020 2020 FY
2017 $9,000 -$48,000 -123% 01 Jul 2016 30 Jun 2017 10-K 27 Sep 2019 2019 FY
2016 $39,000 01 Jul 2015 30 Jun 2016 10-K 26 Sep 2018 2018 FY
2013 $3,296,299 +$192,552 +6.2% 01 Jul 2012 30 Jun 2013 10-K 30 Sep 2013 2013 FY
2012 $3,103,747 +$93,583 +3.1% 01 Jul 2011 30 Jun 2012 10-K 30 Sep 2013 2013 FY
2011 $3,010,164 01 Jul 2010 30 Jun 2011 10-K/A 26 Oct 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.